Report documents measurable gains in trust, participation, and access to clinical trials amid healthcare industry headwinds.BIRMINGHAM, Ala., Jan. 28, 2026...
DELRAY BEACH, Fla., Jan. 28, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the eClinical Solutions Market is projected to grow from about...
January 26 Presentation highlighted Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposureBARDA has...
January 26 Presentation highlighted Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposureBARDA has...
~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / January...
~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / January...
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE...
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J.,...
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American...
TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0),...
Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market Company anticipates...
Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical DataMOUNTAIN...
WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product...
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the...
-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026...
• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’...
- TRPML1 is a promising target1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in...
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trialsBOSTON, Jan. 28,...
Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and...